OrthoPediatrics (NASDAQ:KIDS) Upgraded by Wall Street Zen to Hold Rating

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Friday.

Several other analysts also recently commented on KIDS. Piper Sandler cut their target price on OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Truist Financial cut their target price on OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. Needham & Company LLC reiterated a "buy" rating and set a $42.00 target price on shares of OrthoPediatrics in a research note on Thursday, May 8th. Lake Street Capital initiated coverage on OrthoPediatrics in a research note on Monday, April 7th. They set a "buy" rating and a $37.00 target price on the stock. Finally, Stifel Nicolaus dropped their price target on OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, March 5th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, OrthoPediatrics currently has a consensus rating of "Moderate Buy" and an average price target of $35.83.

OrthoPediatrics Stock Down 1.8%

Shares of OrthoPediatrics stock traded down $0.40 during midday trading on Friday, hitting $21.37. The company had a trading volume of 245,620 shares, compared to its average volume of 200,706. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.99 and a current ratio of 6.19. The stock has a market capitalization of $519.08 million, a P/E ratio of -12.21 and a beta of 1.08. The company has a 50 day moving average of $21.39 and a 200 day moving average of $23.07. OrthoPediatrics has a 52-week low of $19.52 and a 52-week high of $35.99.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.13). OrthoPediatrics had a negative return on equity of 7.03% and a negative net margin of 19.15%. The company had revenue of $52.41 million during the quarter, compared to analysts' expectations of $51.68 million. On average, equities analysts predict that OrthoPediatrics will post -0.93 earnings per share for the current fiscal year.

Hedge Funds Weigh In On OrthoPediatrics

A number of institutional investors and hedge funds have recently modified their holdings of KIDS. KLP Kapitalforvaltning AS purchased a new position in shares of OrthoPediatrics in the 4th quarter worth $79,000. Wells Fargo & Company MN boosted its stake in shares of OrthoPediatrics by 31.1% in the 4th quarter. Wells Fargo & Company MN now owns 9,853 shares of the company's stock worth $228,000 after buying an additional 2,338 shares during the last quarter. PDT Partners LLC bought a new position in OrthoPediatrics in the 1st quarter worth $244,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in OrthoPediatrics by 6.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company's stock worth $246,000 after purchasing an additional 645 shares during the period. Finally, GAMMA Investing LLC raised its holdings in OrthoPediatrics by 4,618.2% in the 1st quarter. GAMMA Investing LLC now owns 10,616 shares of the company's stock worth $261,000 after purchasing an additional 10,391 shares during the period. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.